← Back to headlines
Quoin Pharmaceuticals Reports Positive Phase 2/3 Data for Netherton Syndrome Treatment
Quoin Pharmaceuticals announced encouraging interim results from its ongoing clinical trial of QRX003, a potential therapy for the rare genetic skin disorder Netherton Syndrome.
28 Aug, 10:00 — 28 Aug, 10:00
